ALB and End Stage Liver Disease: Many studies have been conducted to improve the performance of the NITs in excluding HRVs (Abraldes et al., 2016), such as expanded Baveno VI criteria (LSM <25 kPa and PLT >110×109/L, EB6C criterion) (Augustin et al., 2017b); PLT >150×109/L and model for end-stage liver disease (MELD) score = 6 (P150M6 criterion) (Jangouk et al., 2017); PLT >120×109/L and albumin (ALB) >36 g/L (P120A36 criterion) (Calvaruso et al., 2019); and ALB-bilirubin (ALBI) grade and PLT score (ALBI-PLT score) (Abd Elbaser et al., 2022).